Trial Search Results
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Stanford is currently not accepting patients for this trial.
Janssen Biotech, Inc.
Collaborator: Pharmacyclics LLC.
- Drug: Ibrutinib
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or
refractory disease after prior therapy are eligible.
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent are
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study